12:00 AM
May 14, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

BL&H, Clinigen Group, Hospira, AstraZeneca sales and marketing update

Clinigen's Clinigen Healthcare division granted BL&H exclusive rights to commercialize Foscavir foscarnet in South Korea. The companies will collaborate on regulatory approval for the product to treat herpes, cytomegalovirus (CMV) infection and CMV in...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >